Circadian Thermal Sensing to Detect Breast Disease

Early-Stage Breast Carcinoma Clinical Trial

Official title:

Circadian Thermal Sensing for the Detection of Breast Disease as a Supplemental Cancer Screening System

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT02511301
• Other study ID #: CH001
• Status: Recruiting
• Phase: Phase 1/Phase 2
• Start date: June 2015
• Est. completion date: February 2020

Study information

• Verified date: December 2018
• Source: Cyrcadia Health
• Contact: Marie Norell, B.A., CCRA
• Phone: 775-233-1211
• Email: manorell[@]cyrcadiahealth.com
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

The purpose of this study is to determine if Cyrcadia's Circadian Biometric Recorder (CBR™), which is attached to soft biometric patches worn on the body, can improve early breast cancer detection along with mammography or as a stand alone device.

Description:

The Cyrcadia CBR™ (Circadian Biometric Recorder) includes wearable biometric patches and a detachable data recording device. The CBR™ records chronobiologic data while the patient is totally ambulatory and going about her normal daily routine. Following removal of the detachable data recording device from the wearable biometric patches, the data is transferred to a computer for analysis. The Cyrcadia CBR™ will be placed on the patient for the duration of 2 to 24 hours. There is no restriction of daily activity. The study subject is requested to sponge bathe rather than shower while wearing the device, keeping the device dry during the testing procedure. After this period, the CBR™ will be removed and the data will be transferred to a computer for analysis.

The primary endpoint of this 173 patient study is to determine the accuracy of Cyrcadia CBR™ as a supplemental screening device to mammography and ultrasound in predicting a diagnosis of breast cancer. Specific emphasis will be on the utilization of the CBR as a secondary screening device to reduce the number of biopsies currently performed on non-cancerous tissue. A secondary emphasis will be on the CBR to act as an improved screening solution over mammography specifically in those patients with dense breast parenchymal tissue.

Other endpoints of the study are:

• to determine the accuracy of Cyrcadia CBR™, including the positive predictive value, negative predictive value, false negative rate and false positive rate.

• to determine the optimal wear time for the Cyrcadia CBR™.

• to demonstrate substantial equivalent or improved results when applied to Cyrcadia original patient case study with identical advanced neural network analysis computational results.

Study subjects will be followed at 6, 12, 18, and 24 months to update their clinical status.

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 173
• Est. completion date: February 2020
• Est. primary completion date: February 2020
• Accepts healthy volunteers: No
• Gender: Female
• Age group: 21 Years and older

Eligibility

Inclusion Criteria:

• Women with a BI-RADS category 4 or 5 designation on mammogram

• Women with a BI-RADS category 4 or 5 designation on breast ultrasound

• Women with a BI-RADS category 4 or 5 designation on breast MRI

• Women who are willing to undergo a complete evaluation and/or biopsy procedure if recommended by the treating physician

Exclusion Criteria:

• Less than 21 years of age

• Unable to sign the consent form

• Pregnant or lactating

• Physically unable to wear the Cyrcadia CBR™ for 6 hours

• Previous mastectomy

• Any breast surgery or biopsy within the last 90 days

• Any trauma to the breast within the last 90 days

• Any biopsy or treatment for the BI-RADS category 4 or 5 abnormality

• Refusal to undergo recommended diagnostic evaluation of the BI-RADS category 4 or 5 abnormality

Related Conditions & MeSH terms

• Breast Diseases
• Breast Neoplasms
• Early-Stage Breast Carcinoma

Intervention

Device:
• Cyrcadia CBR™ device placement for abnormality screening
Cyrcadia CBR™ device, including adhesive patches on both breasts connected to a small recorder, is placed on the study subject for 2 to 24 hours. After the test period, the CBR™ will be removed and the data will be downloaded to a central site for analysis. There are no interventions after the CBR™ is removed from the Study Subject.

Locations

Country	Name	City	State
United States	The Ohio State University, Stephanie Spielman Comprehensive Cancer Center	Columbus	Ohio
United States	El Camino Hospital	Mountain View	California

Sponsors (4)

Lead Sponsor	Collaborator
Cyrcadia Health	Ohio State University, Salesforce, Stanford University

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Predictive Analytic Analysis (PAA) Sensitivity and Specificity	The data is analyzed using a predefined set of algorithms, referred to as Predictive Analytic Analysis (PAA) Outcome is measured by: NUMBER OF PATIENTS WHOSE INVESTIGATIVE CBR DEVISE RESULTS MATCH OF THOSE OF THE BIOPSY RESULTS.	7 to 30 days after CBR placement